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1  | INTRODUC TION
Beta‐adrenergic blocking agents (β‐blockers) are part of the standard 
care in prevention or treatment of cardiovascular disease such as 
myocardial infarction, heart failure, arrhythmias, and hypertension, 
making β‐blockers some of the most widely used prescription drugs 
worldwide.1 β‐blockers have shown significantly reduced mortality 
rates in heart failure patients and is the cornerstone in prevention 
of sudden cardiac death in long QT syndrome (LQTS) patients.2,3 β‐
blockers have thus in heart failure shown “marked beneficial effects, 
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Abstract
The aim of this study was to evaluate the pharmacokinetic variability of beta‐adren‐
ergic blocking agents used in cardiology by reviewing single‐dose and steady‐state 
pharmacokinetic	studies	from	the	literature.	PubMed	was	searched	for	pharmacoki‐
netic studies of beta‐adrenergic blocking agents, both single‐dose and steady‐state 
studies. The studies included reported maximum plasma concentration (Cmax) and/
or	area	under	the	concentration	curve	(AUC).	The	coefficient	of	variation	(CV%)	was	
calculated for all studies, and a CV% <40% was considered low or moderate vari‐
ability, and a CV% >40% was considered high variability. The Cmax	 and	AUC	were	
reported	a	total	of	672	times	in	192	papers.	Based	on	AUC,	metoprolol,	proprano‐
lol, carvedilol, and nebivolol showed high pharmacokinetic variability (highest first), 
whereas bisoprolol, atenolol, sotalol, labetalol, nadolol, and pindolol showed low to 
moderate variability (lowest first). We have shown a high interindividual pharmacoki‐
netic variability that varies markedly in different beta‐adrenergic blocking agents; the 
extreme	being	steady	state	ratios	as	high	as	30	in	metoprolol.	A	more	personalized	
approach to the medical treatment of patients may be obtained by combining known 
pharmacokinetic information about variability, pharmaco‐genetics and ‐dynamics, 
and patient characteristics, to avoid adverse events or lack of treatment effect.
K E Y W O R D S
beta‐adrenergic	blocking	agents,	metoprolol,	personalized	medicine,	Pharmacokinetics,	
pharmacology, propranolol
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on cardiac function, morbidity, and survival”.4 The clinical effects 
are, however, affected by significant intraclass and interpatient 
variability.4
It is important to distinguish between different attributes (intra‐
class variability) among β‐blockers and the interpatient variability in 
clinical responses. The clinical response depends on a multitude of 
varying factors: pharmacokinetic variability of the drug, variability 
of the pharmacodynamics, eg dose–response curves, variability of 
the disease treated, drug–drug interactions, and presence of comor‐
bidity. Therefore, clinicians cannot assume a “class effect” with all 
β‐blockers.5
The subject of the present review is the interindividual pharma‐
cokinetic variability for each of the β‐blockers with a proven efficacy 
in cardiology, with an emphasis on aspects relevant for the thera‐
peutics of these drugs.
The influence of the pharmacokinetic factors absorption, distri‐
bution,	metabolism,	and	excretion	(ADME)	are	of	relevance	when	a	
varied drug response in patients is observed.6 Interindividual differ‐
ences such as permeability in the intestines, binding to serum pro‐
teins, first–pass metabolism, and degree of renal insufficiency with 
regards to hydrophilic β‐blockers are important regarding pharma‐
cokinetics.	Cytochrome	p450	2D6	(CYP2D6)	gene	expression	is	an	
example of this, as it induces increased exposure and risk of adverse 
events	in	poor	metabolizers	of	metoprolol,	while,	on	the	other	hand,	
a regular dose of metoprolol administered to an ultrarapid metabo‐
lizer	might	prove	ineffective.7,8
Ultimately,	 an	 untargeted	 β‐blocker dosing has retrospectively 
shown to significantly increase mortality in patients with chronic 
systolic heart failure patients compared to target dose or target 
heart rhythm, why a more targeted approach may improve the out‐
come when initiating β‐blocker treatment.9
Numerous clinical studies on the pharmacokinetics of β‐blockers 
have been conducted since the 1960’s.10,11 The purpose of this study 
is	to	review	and	analyze	the	pharmacokinetic	variability	of	β‐block‐
ers in healthy individuals who received single or multiple doses in 
pharmacokinetic studies to provide some guidance for safer and per‐
sonalized	use	of	β‐blockers in the clinic and diminish adverse events 
or ineffectiveness of treatment in patients.
2  | METHODS
We	searched	PubMed	until	 June	2018	for	studies	on	pharmacoki‐
netics of 14 β‐blockers used in clinical cardiology and which have 
demonstrated	superiority	over	placebos	in	at	least	two	randomized	
controlled	 trials	 (RCTs):	 Atenolol,	 betaxolol,	 bisoprolol,	 carvedilol,	
esmolol, labetalol, metoprolol, nadolol, nebivolol, oxprenolol, pindo‐
lol, propranolol, sotalol, and timolol.
PubMed	 was	 searched	 for	 each	 drug	 with	 the	 terms	 “generic	
drug name” and “pharmacokinetics” for both single‐dose and steady‐
state	 studies:	 I	 “generic	 name	AND	 pharmacokinetics	 AND	 single	
dose”	for	single‐dose	studies;	II	“generic	name	AND	pharmacokinet‐
ics	AND	(steady	state	OR	multiple	dose)”	for	steady‐state	studies.
The pharmacokinetic results in oral single‐dose or steady‐state 
studies in healthy adult volunteers were included for analysis of vari‐
ability. Persons with arterial hypertension, but with normal hepatic 
and renal function, were included. Studies with a β‐blocker and an 
oral placebo administered simultaneously were included, while stud‐
ies with simultaneous intake of other medication were excluded. 
Studies presenting only results as means or individual data in figures 
were excluded from this study, since no coefficient of variation (CV) 
could be calculated.
The pharmacokinetic variability was expressed as the CV for 
the maximum plasma concentration (Cmax) and the area under the 
concentration	curve	(AUC).	For	Cmax	and	AUC,	we	classified	the	CV	
of each study (single‐dose or steady‐state) as: <20%, 20%‐40%, 
40%‐60%, 60%‐80%, or > 80%.
The variability of the pharmacokinetic parameters was most 
often presented in the individual studies as mean and standard devi‐
ation	(SD)	or	as	mean	and	standard	error	of	the	mean	(SEM).	SD	was	
used	to	calculate	the	CV:	CV	=	SD/mean.	SEM	was	calculated	back	to	
SD	with	the	formula:	SD	=	SEM	
√
n with n being the number of sub‐
jects studied, and the calculated SD was then used in calculating CV.
The pharmacokinetic variability of a drug for each study was 
divided into two categories: high (CV > 40%) and low or moderate 
(CV	<	40%)	variability	as	proposed	by	Rowland	and	Tozer.12
When	available,	the	ratio	of	maximum	to	minimum	value	of	AUC	
between participants was presented or could be obtained from the 
presented	 raw	data,	with	 the	AUC	 ratio	 being	 the	maximum	AUC	
value	divided	by	the	minimum	AUC	value.
3  | RESULTS
Overall, we included a total of 192 publications investigating the 
pharmacokinetics of oral β‐blockers among healthy individuals and 
persons with hypertension. Thirteen β‐blockers were included, see 
Table 1. While we initially identified 14 different β‐blockers that are 
commonly used for treatment of cardiovascular disease, we were 
only able to identify studies on 13 of these, as no pharmacokinetic 
studies on esmolol were identified. No steady‐state pharmacoki‐
netic studies were found for timolol.
The Cmax	was	reported	in	225	single‐dose	and	101	steady‐state	
pharmacokinetic studies of β‐blockers,	and	 the	AUC	was	 reported	
in 233 single‐dose studies and 113 steady‐state pharmacokinetic 
studies. Table 1 shows the distribution of numbers of studies with 
CV < 20%, 20%‐40%, 40%‐60%, 60%‐80%, or > 80% for Cmax and 
AUC	in	single‐dose	and	steady‐state	pharmacokinetic	studies	of	the	
13 β‐blockers.
The	distribution	of	CVs	for	AUCs	in	single‐dose	and	steady‐state	
studies being < 40% (low or moderate variability) or > 40% (high 
variability) is shown in Table 2. The number of studies for each β‐
blocker ranged from two studies to 111 studies. Propranolol and 
metoprolol show a somewhat identical number of studies with a CV 
of	AUC	>	40%	in	both	single‐dose	and	steady–state	studies	(69%	and	
92% vs. 84% and 80%, respectively).
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The	variability	of	the	CV%	for	AUC	in	steady‐state	studies	with	fixed	
time	points	as	well	as	in	single‐dose	studies	with	time	from	zero	calcu‐
lated	to	infinity	using	the	trapezoid	rule	for	AUC	is	illustrated	in	Figure	1.
In	 the	 steady‐state	 studies	 95%	 of	 studies	were	 conducted	 in	
Europe	or	North	America	and	5%	in	Asia.	The	median	lower	age	limit	
of participants was 21 years (interquartile range, IQR, 20‐23) and 
median	upper	age	limit	37	(IQR	32‐45).	Approximately	75%	of	stud‐
ies specified the sex of participants. The sex ratio was 8:1 (males to 
females).
In	single‐dose	studies	70%	of	studies	were	conducted	in	Europe	
or	North	America,	29%	in	Asia,	and	1%	in	South	America,	the	median	
lower	age	limit	of	participants	was	21	years	(IQR	19.5‐23)	and	me‐
dian	upper	age	limit	42	(IQR	34‐55).	The	sex	ratio	was	4:1.
An	overview	of	 the	pharmacokinetic	properties	of	 the	 studied	
β‐blockers is shown in Table 3.
For	CV	<	40%	(low	or	moderate	variability)	the	median	AUC	ratio	
for single‐dose studies was 2.4 (range 1.1‐4.6; n = 28); for CV > 40% 
(high	variability)	 the	median	AUC	ratio	for	single‐dose	studies	was	
5.8	(range	2.0‐46;	n	=	29).
For	 CV	 <	 40%	 (low	 or	 moderate	 variability)	 the	 median	 AUC	
ratio	 for	 steady‐state	 studies	 was	 2.0	 (range	 1.7‐4.4;	 n	 =	 6);	 for	
CV	>	40%	 (high	variability)	 the	median	AUC	ratio	 for	steady‐state	
studies	was	5.1	(range	1.9‐29.5;	n	=	11).	The	highest	ratio	was	found	
in metoprolol.
4  | DISCUSSION
Our main finding is a considerable interindividual pharmacokinetic 
variability in a subset of β‐blockers used in the treatment of several 
cardiovascular conditions. In particular, carvedilol, metoprolol, ne‐
bivolol, and propranolol showed a high frequency of studies with 
high pharmacokinetic variability (CV > 40%), whereas atenolol, biso‐
prolol, labetalol, nadolol, pindolol, and sotalol showed low or moder‐
ate variability (CV < 40%).
The optimal β‐blocker provides the desired lowered risk of myo‐
cardial	infarction	and	sudden	cardiac	death	as	well	as	minimizes	the	
number of adverse events, both minor and major.13 In clinical use 
β‐1‐selective and nonselective β‐blockers are similar with regards to 
antihypertensive, antiarrhythmic, and antianginal effect, when ade‐
quately dosed.14 When deciding on which β‐blocker to prescribe a 
patient in the clinic, known contradictions should be asserted eg he‐
patic impairment, renal insufficiency, diabetes, and obstructive lung 
disease. In addition, patients who are prescribed β‐blockers often 
have comorbidities and are therefore treated with multiple drugs that 
may have a pharmacokinetic interaction with a subsequent change in 
drug concentration.15 This interaction has been shown with metop‐
rolol and the SSRI fluoxetine (CYP2D6 inhibitor), which increase the 
concentration of metoprolol thus inducing bradycardia.16
As	shown	in	this	review,	the	AUC	varies	between	individuals	re‐
ceiving the same dosage of eg metoprolol with the most extreme 
ratio	of	30‐fold	from	highest	to	lowest	AUC.17
Differences in pharmacokinetic parameters of β‐blockers are ap‐
parent in patients when comparing healthy individuals with patients 
with kidney or liver disease, but differences are also present among 
apparently comparable healthy subjects as seen in this review and 
can	largely	be	explained	by	the	four	ADME	phases:
Bioavailability of β‐blockers varies in part because of first–pass 
hepatic elimination resulting in a varying oral bioavailability, see 
Table 3. This is further complicated by food–induced changes in the 
TA B L E  2  Distribution	of	coefficients	of	variance	(CV)	for	area	under	the	plasma	concentration‐time	curve	(AUC)	in	pharmacokinetic	
studies of beta‐adrenergic blocking agents where the CVs were > 40% (high variability)
Drug
Number (%) of single‐dose studies with 
CV > 40% for AUC
Number (%) of steady‐state studies 
with CV > 40% for AUC
References (Supplementary 
Materials)
Atenolol 5/36	(14) 0/4 (0) 41,42,51,54
Betaxolol 0/1 (0) 0/1 (0)  
Bisoprolol 0/10 (0) 0/2 (0)  
Carvedilol 10/12 (83) 1/1 (100) 73,74,76,78,80,81
Labetalol 5/14	(36) 1/4	(25) 55,86,89
Metoprolol 41/49 (84) 32/40 (80) 17,38,58,65,91‐98,100‐107,109‐115,117‐123,12
6‐131,135‐141
Nadolol 1/6	(17) 3/6	(50) 145,146
Nebivolol 8/11	(73) 1/1 (100) 148‐150,152‐155
Oxprenolol 1/4	(25) 2/3 (66) 122,126,158
Pindolol 3/11	(27) 4/7	(57) 163,165‐167
Propranolol 40/58	(69) 36/39 (92) 38,42,51,59,62,93,95,128,166,170‐172,175‐178,
180‐182,184‐186,188‐190,194‐205,207‐214
Sotalol 0/14 (0) 1/5	(20) 222
Timolol 5/7	(71) ND 193,223‐225
ND, no data.
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bioavailability, where food induces a 20% reduction in the bioavail‐
ability of atenolol, while it tends to enhance the bioavailability in 
metoprolol	(40%)	and	propranolol	(53%).18‐20 In the pharmacokinetic 
studies in this review the participants were generally fasting prior 
to receiving the test formulation in single‐dose studies, while the 
participants in steady‐state studies also abstained from food‐intake 
prior to receiving the test formulation.
The metabolism and elimination of β‐blockers depends partly on 
whether the β‐blocker is lipophilic, in which case it is almost com‐
pletely	metabolized	by	the	liver,	or	hydrophilic,	in	which	case	elimi‐
nation is mainly dependent on glomerular filtration.21 In this review, 
hydrophilic β‐blockers (atenolol, nadolol, sotalol) showed a gener‐
ally	 lower	number	of	 studies	where	CV%	 for	AUC	was	>	40%.	As	
atenolol, nadolol, and sotalol avoid first–pass metabolism in the liver, 
F I G U R E  1   Cloud plot of the distribution of the coefficient of variance (CV) in beta‐adrenergic blocking agents for the area under the 
plasma‐concentration	time	curve	(AUC)	in	steady‐state	studies	(SS)	and	in	single‐dose	(SD)	studies	with	AUC	extrapolated	to	infinity
Drug
Extent of 
absorption (% of 
dose)
Bioavailability 
(% of dose)
Major first–pass 
hepatic metabolism Lipid solubility
Atenolol ≈50 ≈40 No Low
Betaxolol >90 ≈80 No Low
Bisoprolol ≈90 ≈88 No Low
Carvedilol >90 ≈30 Yes Moderate
Labetalol >90 ≈33 Yes Moderate
Metoprolol >90 ≈50 Yes Moderate
Nadolol ≈30 ≈30 No Low
Nebivolol >90 12‐96 Yes Lowa
Oxprenolol ≈90 19‐74 Yes Moderate
Pindolol >90 ≈90 No Moderate
Propranolol >90 30‐70 Yes High
Sotalol >80b ≈90 No Low
Timolol >90 ≈75 Yes Low‐moderate
aFrom.34 
bFrom.21 
TA B L E  3   Pharmacokinetics properties 
of beta‐adrenergic blocking agents (with 
permission from Frishman22 and publisher)
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the interindividual pharmacokinetic variation in bioavailability may 
not be as extensive in hydrophilic β‐blockers.22 On the contrary, all 
the β‐blockers showing high pharmacokinetic variability in our re‐
view	are	metabolized	primarily	in	the	liver	mediated	by	the	CYP2D6	
enzyme.
The liver metabolism has been shown to be highly dependent on 
the	phenotype	of	the	individual,	where	poor	metabolizers,	in	theory,	
are more prone to experience adverse events compared to extensive 
metabolizers,	because	of	a	 lower	needed	dosage.8 but, in practice, 
this theory has not been validated in studies on metoprolol.23,24 This 
discrepancy could be attributed to differences in the sympathetic 
tone in patients or a rather flat dose–response curve in some β‐
blockers.22 We have compared extended release formulations with 
regular tablets of metoprolol in steady‐state studies and found the 
median	CV	for	AUC	to	be	lower	for	extended	release	formulations	
(54%	vs.	72%),	but	no	substantial	differences	were	seen	for	the	me‐
dian CV for Cmax. But as this is only descriptive, a meta‐analysis of 
the studies should be done to make any statistical conclusions on the 
effect of extended release formulations’ effect on the pharmacoki‐
netics of β‐blockers.
The	 ratios	 for	AUC	 in	both	 single‐dose	 and	 steady‐state	 stud‐
ies	 corresponded	with	 the	 variability	 seen	 for	CV%	 for	AUC.	 The	
interpatient	 variability	 was	 expressed	 as	 the	 CV	 for	 AUC,	 which	
likely is the most relevant parameter for clinical use of the β‐block‐
ers.	Rowland	and	Tozer	showed	the	AUC	to	infinity	for	a	single	oral	
dose	to	be	equal	to	the	AUC	to	time	in	steady‐state	studies,	and	thus	
we	 included	 results	 from	 single‐dose	 studies	 on	AUC	 in	 Figure	 1:	
AUCSS,0−휏 =AUCSD,0−∞.
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The pharmacokinetic results in this review, obtained from sev‐
eral studies, are primarily deducted from young to middle aged 
healthy male individuals, thereby potentially underestimating the 
true potentially greater pharmacokinetic differences found in el‐
derly patients, who are the main recipients of β‐blockers and often 
are in medical treatment for other comorbidities. Only a few stud‐
ies included in this review subdivided the volunteers in a “young” 
and “elderly” category, but pharmacokinetic results from these 
studies point in different directions. Castleden et al showed an ef‐
fect of aging on the pharmacokinetics of propranolol both in single 
and steady‐state doses: the elderly not only had a 2.3 times higher 
Cmax in the single‐dose study, but the steady‐state study showed 
an overall plasma concentration of 3.1 times higher compared to 
the young.25 Castleden et al explains this difference as a result 
of reduced hepatic blood flow and first–pass extraction in the el‐
derly, which is important as a majority of prescriptions are for the 
elderly population.
More	 than	 100	 different	 CYP2D6	 gene	 polymorphisms	 have	
been	 identified	 since	 the	1970s.8 These genetic variants form the 
basis of the four phenotypes: ultrarapid, extensive, intermediate, 
and	poor	metabolizers	of	medication	metabolized	by	 the	CYP2D6	
enzyme.	The	pharmacokinetic	differences	 in	patients	cause	differ‐
ent bioavailability between patients even though the same drug dos‐
age	has	been	administered;	consequently,	extensive	metabolizers	of	
the	CYP2D6	enzyme	will	need	markedly	higher	doses	of	metoprolol	
than	 poor	metabolizers	 to	 obtain	 the	 same	 plasma	 concentration.	
Blake et al compared the Cmax	and	AUC	of	metoprolol	in	ultrarapid	
metabolizers	and	poor	metabolizers	in	a	pooled	analysis	and	found	
a	 5.3‐fold	 (Cmax/dose; 90% confidence interval (CI): 3.6‐6.9‐fold; 
P <	 0.0001)	 and	 13‐fold	 (AUC/dose;	 90%	CI:	 9.4‐19.7‐fold)	 differ‐
ence, respectively.11
The clinical implications of our results are the substantial dif‐
ferences in interpatient pharmacokinetic variability in different β‐
blockers.	 Administration	 of	 β‐blockers with high pharmacokinetic 
variability should be more cautiously initiated, as the daily mainte‐
nance dose varies more from patient to patient. Combined with the 
membrane–stabilizing	 effect	 of	 nadolol,	 the	 low	 pharmacokinetic	
variation may explain why nadolol is the most efficient β‐blocker to 
reduce life–threatening arrhythmic events in LQTS patients.26	As	il‐
lustrated in Figure 1, the pharmacokinetic variability of carvedilol is 
found to be approximately 60%, which is in conjunction with find‐
ings in Packer et al's study on the lowering morbidity and mortality 
of carvedilol in patients with heart failure, where a steady state dos‐
age	of	45	±	27	mg	(60%	CV)	of	carvedilol	was	seen.27
Difference in β‐1 selectivity/nonselectivity among β‐blockers 
and the potency of said β‐blocker are important factors when de‐
ciding on β‐blocker to a patient, comorbidities considered.28 Genetic 
polymorphisms for the β‐1 adrenoceptor have been identified and 
investigated in relation to pharmacodynamic variability, but the no 
clear relation has been shown.29 Receptor antagonism of the adren‐
ergic β‐1 receptor induces lowered sympathetic activation thereby 
lowering the heart rate and contractility of the heart, while antag‐
onism of the β‐2 receptor may induce vasoconstriction of smooth 
muscle cells in the bronchi and blood vessels, why asthma patients 
should avoid nonselective β‐blockers.30 Nonselective β‐blockers 
may also mask symptoms of hypoglycemia in diabetics.30
A	major	limitation	of	our	findings	is	the	number	of	studies	con‐
ducted on the different types of β‐blockers; the β‐blockers that have 
been on the market for the longest time have had a large amount 
of studies conducted compared to newer as well as rarely used β‐
blockers.	Metoprolol	and	propranolol	are	often	used	in	comparative	
studies with newer formulations.
Factors such as sex, obesity, and ethnicity have also been proved 
to be of importance in the pharmacokinetics.31,32	Ueno	et	al	have	
previously reviewed sex–specific differences in pharmacokinetic 
studies of metoprolol and propranolol, where females had greater 
drug exposure than males in part due to different body composi‐
tion.31 The studies included in our review were mainly conducted 
on	healthy	Caucasian	male	volunteers	with	a	BMI	of	20‐25,	and	the	
investigation of sex–specific differences in the pharmacokinetics 
was not possible in the current study. The subjects were typically 
matched on sex, body weight, age, and health status, and crossover 
studies	were	generally	conducted.	A	few	studies	differentiated	on	
CYP2D6‐status,	while	 in	most	 studies	 it	was	 not	 investigated.	 As	
the findings from this review are related to healthy volunteers, the 
known influence of eg age, sex, genotype, and comorbidities in the 
elderly will in theory further increase the interindividual pharmaco‐
kinetic variability.
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Future research should focus on the matter that, as genetic test‐
ing is becoming more common, available data obtained from here 
should somehow be included in the clinicians’ considerations when 
prescribing a patient a β‐blocker, eg if the patient is a poor metab‐
olizer	of	metoprolol	thereby	reducing	the	initial	dosage	in	combina‐
tion	with	the	patient's	general	characteristics	(sex,	age,	BMI).33
The beneficial effects of β‐blockers in eligible patients are strong 
and the impact has caused β‐blockers to be considered one of the 
greatest pharmacotherapeutic advances of the 20th century. The 
pharmacology is widely understood, but the individual response is 
often unpredictable and should lead to a careful up‐titration of the 
medication.
In conclusion, we showed how the pharmacokinetic variability 
between patients vary markedly in different β‐blockers, and we 
showed how the ratios between highest and lowest steady‐state 
concentrations differ with the highest ratio in metoprolol being 30.
By combining known pharmacokinetic information with pharma‐
cogenetic findings (CYP‐status for lipophilic β‐blockers) with phar‐
macodynamics (pulse or blood pressure) and the individual patient's 
characteristics,	a	more	personalized	treatment	may	be	obtained	 in	
the	future,	minimizing	adverse	events	or	lack	of	effect.
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